Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Iniparib + Irinotecan |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Iniparib | BSI-201|SAR240550 | Iniparib (BSI-201) appears to modify cysteine-containing proteins in tumor cells, and has minimal activity as a PARP inhibitor (PMID: 22128301, PMID: 22291137, PMID: 31172407, PMID: 30131387). | ||
Irinotecan | Camptosar | CPT-11 | TOPO1 inhibitor 11 | Camptosar (irinotecan) inhibits Topoisomerase-I activity, resulting in inhibition of DNA replication, and potentially leading to cell death and is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic or recurrent colorectal carcinoma (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01593228 | Phase III | Carboplatin + Doxorubicin + Iniparib Iniparib + Paclitaxel Iniparib + Irinotecan Iniparib + Topotecan Carboplatin + Gemcitabine + Iniparib Iniparib | Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial | Completed | USA | ITA | ESP | BEL | 0 |